Pharvaris (NASDAQ:PHVS) Cut to Sell at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also weighed in on the stock. Wedbush increased their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Leerink Partners set a $38.00 price objective on Pharvaris in a research report on Wednesday, December 3rd. Finally, Bank of America increased their target price on Pharvaris from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Thursday, December 4th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.56.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $28.39 on Friday. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -8.84 and a beta of -2.79. Pharvaris has a 1-year low of $11.51 and a 1-year high of $29.80. The company’s fifty day moving average is $26.68 and its two-hundred day moving average is $24.71.

Institutional Trading of Pharvaris

Several hedge funds have recently added to or reduced their stakes in PHVS. Seven Fleet Capital Management LP acquired a new position in Pharvaris during the 4th quarter worth $1,536,000. XTX Topco Ltd raised its stake in shares of Pharvaris by 126.1% during the fourth quarter. XTX Topco Ltd now owns 18,568 shares of the company’s stock valued at $515,000 after purchasing an additional 10,355 shares in the last quarter. Ikarian Capital LLC raised its stake in shares of Pharvaris by 131.7% during the fourth quarter. Ikarian Capital LLC now owns 486,856 shares of the company’s stock valued at $13,510,000 after purchasing an additional 276,691 shares in the last quarter. Virtus Investment Advisers LLC lifted its holdings in Pharvaris by 66.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company’s stock worth $306,000 after purchasing an additional 4,407 shares during the period. Finally, SummitTX Capital L.P. bought a new position in Pharvaris in the 4th quarter valued at about $634,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.